HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Future Of CBD In Supplements: NDI Notification Looms As Regulatory Path

Executive Summary

Recent statement that FDA has not found evidence supporting CBD as GRAS for use in human or animal food potentially points to NDI notifications as the only option manufacturers, marketers and other businesses will have to convince agency about safety for CBD and other hemp-derived substances used in dietary supplements.

You may also be interested in...

CV Sciences Eagerly Anticipating FDA Rulemaking On CBD In Dietary Supplements

Duffy MacKay, senior VP of scientific and regulatory affairs at CV Sciences, offers his predictions regarding the FDA’s likely course in regulating CBD’s use in dietary supplements – action that is sorely needed as the market continues to crowd with CBD products “with who-knows-what in them.”

With CBD's US Consumer Health Future In Limbo, FDA Warns About Injectable Offered OTC

With the rapid growth of CBD supplements, topicals and other consumer health products available in the US, FDA has found no shortage of businesses to warn about making noncompliant claims. Still, it previously hasn't found reason to warn CBD businesses about unsafe delivery formats.

Cannabidiol Safety In Question At US FDA? Exploding Market Suggests Not So Much

A report FDA submitted to Congress earlier in March on determining an enforcement discretion policy for CBD-containing non-drug products did little to indicate it is approaching a decision. It's likely that FDA officials are reasonably confident of CBD's safety in food and supplements because the agency has allowed the market to proliferate.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts